Becker Capital Management Inc. Purchases 5,068 Shares of Johnson & Johnson $JNJ

Becker Capital Management Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 260,197 shares of the company’s stock after purchasing an additional 5,068 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of Becker Capital Management Inc.’s portfolio, making the stock its 21st biggest holding. Becker Capital Management Inc.’s holdings in Johnson & Johnson were worth $39,745,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Investment House LLC grew its stake in Johnson & Johnson by 32.2% in the 2nd quarter. Investment House LLC now owns 95,505 shares of the company’s stock valued at $14,588,000 after buying an additional 23,261 shares in the last quarter. Sei Investments Co. raised its stake in shares of Johnson & Johnson by 8.4% during the 2nd quarter. Sei Investments Co. now owns 1,325,913 shares of the company’s stock valued at $202,534,000 after purchasing an additional 102,781 shares during the period. NewEdge Advisors LLC boosted its stake in Johnson & Johnson by 3.3% in the 2nd quarter. NewEdge Advisors LLC now owns 344,909 shares of the company’s stock worth $52,685,000 after purchasing an additional 11,088 shares during the period. Dymon Asia Capital Singapore PTE. LTD. bought a new position in Johnson & Johnson in the 2nd quarter worth about $2,138,000. Finally, Stamos Capital Partners L.P. increased its position in shares of Johnson & Johnson by 58.7% during the second quarter. Stamos Capital Partners L.P. now owns 65,088 shares of the company’s stock valued at $9,942,000 after buying an additional 24,083 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $209.00 target price on shares of Johnson & Johnson in a report on Friday, October 10th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Argus set a $210.00 price objective on Johnson & Johnson in a research report on Wednesday, October 15th. Stifel Nicolaus upped their target price on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research note on Wednesday, October 15th. Finally, The Goldman Sachs Group lifted their price target on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $204.40.

Johnson & Johnson Stock Up 3.3%

JNJ opened at $206.50 on Thursday. The business’s fifty day simple moving average is $195.15 and its 200 day simple moving average is $176.44. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $207.81. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $497.51 billion, a PE ratio of 19.93, a P/E/G ratio of 2.23 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.